A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma based on a Phase III Trial of CHOP-Rituximab vs CHOP + (131)Iodine-Tositumomab

PURPOSE: There is currently no consensus on optimal front-line therapy for patients with follicular lymphomas (FL). We analyzed a Phase III randomized intergroup trial comparing 6 cycles of CHOP-R with six cycles of CHOP followed by iodine I-131 tositumomab radioimmunotherapy (RIT) to assess whether...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Press, Oliver W., Unger, Joseph M., Rimsza, Lisa M., Friedberg, Jonathan W., LeBlanc, Michael, Czuczman, Myron S., Kaminski, Mark, Braziel, Rita M., Spier, Catherine, Gopal, Ajay K., Maloney, David G., Cheson, Bruce D., Dakhil, Shaker R., Miller, Thomas P., Fisher, Richard I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3872052/
https://ncbi.nlm.nih.gov/pubmed/24130072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1120
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller